|
|
|
| Research progress of Linc-RoR and pancreatic cancer |
| WANG Qianqian1 WANG Huizhi2 XU Min2 |
1.College of Medicine, Jiangsu University, Jiangsu Province, Zhenjiang 212000, China;
2.Department of Gastroenterology, Affiliated Hospital of Jiangsu University, Jiangsu Province, Zhenjiang 212000, China |
|
|
|
Abstract Pancreatic cancer is currently one of the cancers with a poor prognosis. Long non-coding RNA (LncRNA) plays an important role in the diagnosis, treatment and prognosis of pancreatic cancer. As an important member of the lncRNA family, intergenic long non-coding RNA-recoding regulatory factor (Linc-RoR) also plays an important role in pancreatic cancer. Linc-RoR is highly expressed in pancreatic cancer and promotes the proliferation, migration, invasion and drug resistance of pancreatic cancer cells. Linc-RoR is also involved in the stemness maintenance of pancreatic cancer stem cells, and is closely related to the prognosis of pancreatic cancer. Linc-RoR is expected to become a new biomarker and gene therapy target for pancreatic cancer, bringing new hope to the clinical treatment of pancreatic cancer.
|
|
|
|
|
|
[1] Siegel RL，Miller KD，Jemal A. Cancer statistics，2020 [J]. CA Cancer J Clin，2020，70（1）：7-30.
[2] Singhi AD，Koay EJ，Chari ST，et al. Early Detection of Pancreatic Cancer：Opportunities and Challenges [J]. Gastroenterology，2019，156（7）：2024-2040.
[3] Neoptolemos JP，Kleeff J，Michl P，et al. Therapeutic developments in pancreatic cancer：current and future perspectives [J]. Nat Rev Gastroenterol Hepatol，2018，15（6）：333-348.
[4] Zhu H，Li T，Du Y，et al. Pancreatic cancer：challenges and opportunities [J]. BMC Med，2018，16（1）：214.
[5] Bhan A，Soleimani M，Mandal SS. Long Noncoding RNA and Cancer：A New Paradigm [J]. Cancer Res，2017，77（15）：3965-3981.
[6] Lv Y，Huang S. Role of non-coding RNA in pancreatic cancer [J]. Oncol Lett，2019，18（4）：3963-3973.
[7] Ransohoff JD，Wei Y，Khavari PA. The functions and unique features of long intergenic non-coding RNA [J]. Nat Rev Mol Cell Biol，2018，19（3）：143-157.
[8] Loewer S，Cabili MN，Guttman M，et al. Large intergenic non-coding RNA-RoR modulates reprogramming of human induced pluripotent stem cells [J]. Nat Genet，2010， 42（12）：1113-1117.
[9] Wang Y，Xu Z，Jiang J，et al. Endogenous miRNA sponge lincRNA-RoR regulates Oct4，NANOG，and Sox2 in human embryonic stem cell self-renewal [J]. Dev Cell，2013， 25（1）：69-80.
[10] Hou P，Zhao Y，Li Z，et al. LincRNA-ROR induces epithelial-to-mesenchymal transition and contributes to breast cancer tumorigenesis and metastasis [J]. Cell Death Dis，2014，5（6）：e1287.
[11] Zhan HX，Wang Y，Li C，et al. LincRNA-ROR promotes invasion，metastasis and tumor growth in pancreatic cancer through activating ZEB1 pathway [J]. Cancer Lett，2016， 374（2）：261-271.
[12] Chen W，Wang H，Liu Y，et al. Linc-RoR promotes proliferation，migration，and invasion via the Hippo/YAP pathway in pancreatic cancer cells [J]. J Cell Biochem，2020，121（1）：632-641.
[13] Pan Y，Chen J，Tao L，et al. Long noncoding RNA ROR regulates chemoresistance in docetaxel-resistant lung adenocarcinoma cells via epithelial mesenchymal transition pathway [J]. Oncotarget，2017，8（20）：33144-33158.
[14] Li C，Lu L，Feng B，et al. The lincRNA-ROR/miR-145 axis promotes invasion and metastasis in hepatocellular carcinoma via induction of epithelial-mesenchymal transition by targeting ZEB2 [J]. Sci Rep，2017，7（1）：4637.
[15] Chen YM，Liu Y，Wei HY，et al. Linc-ROR induces epi-thelial-mesenchymal transition and contributes to drug resistance and invasion of breast cancer cells [J]. Tumour Biol，2016，37（8）：10861-10870.
[16] Peng WX，Huang JG，Yang L，et al. Linc-RoR promotes MAPK/ERK signaling and confers estrogen-independent growth of breast cancer [J]. Mol Cancer，2017，16（1）：161.
[17] Li C，Zhao Z，Zhou Z，et al. Linc-ROR confers gemcitabine resistance to pancreatic cancer cells via inducing autophagy and modulating the miR-124/PTBP1/PKM2 axis [J]. Cancer Chemother Pharmacol，2016，78（6）：1199-1207.
[18] Li X，Sun D，Zhao T，et al. Long non-coding RNA ROR confers arsenic trioxide resistance to HepG2 cells by inhibiting p53 expression [J]. Eur J Pharmacol，2020，872：172982.
[19] Yang P，Yang Y，An W，et al. The long noncoding RNA-ROR promotes the resistance of radiotherapy for human colorectal cancer cells by targeting the p53/miR-145 pathway [J]. J Gastroenterol Hepatol，2017，32（4）：837-845.
[20] Chen Y，Shen Z，Zhi Y，et al. Long non-coding RNA ROR promotes radioresistance in hepatocelluar carcinoma cells by acting as a ceRNA for microRNA-145 to regulate RAD18 expression [J]. Arch Biochem Biophys，2018， 645：117-125.
[21] 李冰，熊正方，郭亚民.长链非编码RNA ROR通过notch1蛋白调控胰腺癌细胞的增殖凋亡[J].实用医学杂志，2017，33（12）：1922-1927.
[22] Gao S，Wang P，Hua Y，et al. ROR functions as a ceRNA to regulate NANOG expression by sponging miR-145 and predicts poor prognosis in pancreatic cancer [J]. Oncotarget，2016，7（2）：1608-1618.
[23] Fu Z，Li G，Li Z，et al. Endogenous miRNA Sponge LincRNA-ROR promotes proliferation，invasion and stem cell-like phenotype of pancreatic cancer cells [J]. Cell Death Discov，2017，3：17004.
[24] Liu Y，Feng W，Gu S，et al. The UCA1/KRAS axis promotes human pancreatic ductal adenocarcinoma stem cell properties and tumor growth [J]. Am J Cancer Res，2019， 9（3）：496-510.
[25] Toledo-Guzmán ME，Bigoni-Ordó?觡ez GD，Ibá?觡ez Hern-ández M，et al. Cancer stem cell impact on clinical oncology [J]. World J Stem Cells，2018，10（12）：183-195.
[26] Perusina Lanfranca M，Thompson JK，Bednar F，et al. Me-tabolism and epigenetics of pancreatic cancer stem cells [J]. Semin Cancer Biol，2019，57：19-26.
[27] Li C，Heidt DG，Dalerba P，et al. Identification of pancreatic cancer stem cells [J]. Cancer Res，2007，67（3）：1030-1037.
[28] Chaudhary AK，Mondal G，Kumar V，et al. Chemosensitization and inhibition of pancreatic cancer stem cell proliferation by overexpression of microRNA-205 [J]. Cancer Lett，2017，402：1-8.
[29] Mizrahi JD，Surana R，Valle JW，et al. Pancreatic cancer [J]. Lancet，2020，395（10242）：2008-2020.
[30] Zeng S，P?觟ttler M，Lan B，et al. Chemoresistance in Pancreatic Cancer [J]. Int J Mol Sci，2019，20（18）：4504. |
|
|
|
